QBD (QUALITY BY DESIGN) APPROACH: DEVELOPMENT AND VALIDATION OF AN RP-HPLC METHOD FOR ESTIMATING IMEGLIMIN HCL AND ITS KETONE IMPURITY

POOJA T. GIRI; ANURUDDHA R. CHABUKSWAR; SWATI C. JAGDALE; SANTOSH A. CHINDHE

doi:10.22159/ijap.2025v17i4.54506

Authors

POOJA T. GIRI Department of Pharmaceutical Sciences, School of Health Sciences and Technology, Dr. Vishwanath Karad MIT World Peace University, Pune-411038, India https://orcid.org/0009-0003-4867-1540
ANURUDDHA R. CHABUKSWAR Department of Pharmaceutical Sciences, School of Health Sciences and Technology, Dr. Vishwanath Karad MIT World Peace University, Pune-411038, India https://orcid.org/0000-0002-2868-6652
SWATI C. JAGDALE Department of Pharmaceutical Sciences, School of Health Sciences and Technology, Dr. Vishwanath Karad MIT World Peace University, Pune-411038, India https://orcid.org/0000-0003-2914-7420
SANTOSH A. CHINDHE Chemicea Pharmaceutical Pvt. Ltd., Navi Mumbai, India

DOI:

https://doi.org/10.22159/ijap.2025v17i4.54506

Keywords:

Imeglimin hydrochloride, Imeglimin ketone impurity, Quality by design (QBD), RP-HPLC, Central composite design

Abstract

Objective: Quality by Design (QbD) is a structured approach that ensures consistently high-quality outcomes by following a systematic methodology. This study aimed to develop and validate a robust and reliable Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) method for the simultaneous quantification of Imeglimin hydrochloride (IMG) and its ketone impurity, Imeglimin Ketone Impurity (IKI), utilizing a Quality by Design (QbD) approach to ensure enhanced method precision, accuracy, and regulatory compliance.

Methods: A risk-based strategy guided method development, employing the Agilent Zorbax Bonus RP (AZB-RP) column (25 cm×4.6 mm, 5.0 µm) under isocratic elution with a Mobile Phase (MP) of Trifluoroacetic acid (TFA) and Acetonitrile (ACN) (45:55 v/v). Chromatographic conditions included a flow rate of 0.45 ml/min, an injection volume of 10 µl**, and a column temperature of 30 °C. A Central Composite Design (CCD) was applied to study the influence of MP ratio and Flow Rate (FR) on Critical Analytical Parameters (CAPs) using Design Expert 13.0 software.

Results: The method showed excellent linearity with R² = 0.9998 for imeglimin hydrochloride (80–120 ppm) and R² = 0.9994 for its ketone impurity (4–6 ppm) at 238 nm. The recovery was 100.02–100.78% for imeglimin hydrochloride and 99.98–100.02% for the impurity. The Limit of Detection (LOD) and Limit of Quantitation (LOQ) for the impurity were 0.23 ppm and 0.70 ppm, respectively. The Analysis of Variance (ANOVA) results confirmed the model’s significance and predictive ability, highlighting the method’s robustness and reliability for routine quality control applications.

Conclusion: The QbD-based RP-HPLC method described here is accurate, precise, and robust for the simultaneous estimation of IMG and IKI and can be used for routine quality control.

References

Shukla R, Chaudhari A, Patel P, Detholia K. QbD-based RP-HPLC method development for quantitative computation of phase III composition comprising apixaban and clopidogrel. J Appl Pharm Sci. 2024 Aug;14(8):85-93. doi: 10.7324/JAPS.2024.181311.

ICH. Pharmaceutical. Development; 2009. Available from: https://database.ich.org/sites/default/files/Q8_R2_Guideline.pdf. [Last accessed on 10 Jan 2025].

ICH. Quality. Risk Manag; 2023. Available from: https://database.ich.org/sites/default/files/ICH_Q9%28R1%29_Guideline_Step4_2022_1219.pdf. [Last accessed on 11 Jan 2025].

ICH. Pharmaceutical quality system. 2008:Q10. Available from: https://database.ich.org/sites/default/files/Q10%20Guideline.pdf. [Last accessed on 13 Jan 2025].

Orlandini S, Pinzauti S, Furlanetto S. Application of quality by design to the development of analytical separation methods. Anal Bioanal Chem. 2013;405(2-3):443-50. doi: 10.1007/s00216-012-6302-2, PMID 22941176.

Mehta B, Joshi H, Shah U, Patel P. Implementation of qbd principles for simultaneous quantitative expression of olmesartan medoxomil telmisartan and hydrochlorothiazide by RP-HPLC. J Pharm Res Int. 2021;33(41):50-61. doi: 10.9734/jpri/2021/v33i41A32301.

Perry RJ, Cardone RL, Petersen MC, Zhang D, Fouqueray P, Hallakou Bozec S. Imeglimin lowers glucose primarily by amplifying glucose-stimulated insulin secretion in high-fat-fed rodents. Am J Physiol Endocrinol Metab. 2016;311(2):E461-70. doi: 10.1152/ajpendo.00009.2016, PMID 27406738.

Hallakou Bozec S, Vial G, Kergoat M, Fouqueray P, Bolze S, Borel AL. Mechanism of action of imeglimin: a novel therapeutic agent for type 2 diabetes. Diabetes Obes Metab. 2021;23(3):664-73. doi: 10.1111/dom.14277, PMID 33269554.

Yaribeygi H, Maleki M, Sathyapalan T, Jamialahmadi T, Sahebkar A. Molecular mechanisms by which imeglimin improves glucose homeostasis. J Diabetes Res. 2020 Mar 6;2020:8768954. doi: 10.1155/2020/8768954, PMID 32215274.

Dubourg J, Ueki K, Grouin JM, Fouqueray P. Efficacy and safety of imeglimin in Japanese patients with type-2 diabetes: a 24 w randomized double blind placebo controlled dose ranging phase 2b trial. Diabetes Obes Metab. 2021;23(3):800-10. doi: 10.1111/dom.14285, PMID 33275318.

Perry RJ, Cardone RL, Petersen MC, Zhang D, Fouqueray P, Hallakou Bozec S. Imeglimin lowers glucose primarily by amplifying glucose stimulated insulin secretion in high-fat-fed rodents. Am J Physiol Endocrinol Metab. 2016;311(2):E461-70. doi: 10.1152/ajpendo.00009.2016, PMID 27406738.

Vuylsteke V, Chastain LM, Maggu GA, Brown C. Imeglimin: a potential new multi-target drug for type 2 diabetes. Drugs RD. 2015;15(3):227-32. doi: 10.1007/s40268-015-0099-3, PMID 26254210.

Vial G, Chauvin MA, Bendridi N, Durand A, Meugnier E, Madec AM. Imeglimin normalizes glucose tolerance and insulin sensitivity and improves mitochondrial function in liver of a high-fat high sucrose diet mice model. Diabetes. 2015;64(6):2254-64. doi: 10.2337/db14-1220, PMID 25552598.

Lablanche S, Tubbs E, Cottet Rousselle C, Lamarche F, Moisan A, Persoons V. Imeglimin protects INS-1 cells and human islets against high glucose and high fructose induced cell death by inhibiting the mitochondrial PTP opening. Diabetes. 2018;67 Suppl 1:81. doi: 10.2337/db18-81-OR.

Bernardi RM, D Avila FB, Todeschini V, Andrade JM, Froehlich PE, Bergold AM. Main degradation products of dabigatran etexilate evaluated by LC-UV and LC-ESI-MS, degradation kinetics and in vitro cytotoxicity studies. J Braz Chem Soc. 2015;26(4). doi: 10.5935/0103-5053.20150023.

Codevilla CF, Cortivo Lange AD, Maria De Mello Andrade J, Segalin J, Froehlich PE, Bergold AM. Photodegradation kinetics of lodenafil carbonate structure elucidation of two major degradation products using UPLC-MS/MS and in vitro cytotoxicity. Anal Methods. 2013;5(22):6511. doi: 10.1039/c3ay41273c.

Costa MC, Barden AT, Andrade JM, Oppe TP, Schapoval EE. Quantitative evaluation of besifloxacin ophthalmic suspension by HPLC application to bioassay method and cytotoxicity studies. Talanta. 2014 Feb;119:367-74. doi: 10.1016/j.talanta.2013.10.051, PMID 24401427.

Emerce E, Cok I, Degim IT. Determination of the impurities in drug products containing montelukast and in silico/in vitro genotoxicological assessments of sulfoxide impurity. Toxicol Lett. 2015;238(2):90-9. doi: 10.1016/j.toxlet.2015.07.003, PMID 26205398.

ICH. Impurities in new drug products. 2006;Q3B(R2). Available from: https://database.ich.org/sites/default/files/Q3B%28R2%29%20Guideline.pdf. [Last accessed on 12 Jun 2025].

Jahagirdar S, Godge R, Vikhe S, Bornare S. Estimation of imeglimin in pharmaceutical tablets by RP-HPLC. Int J Drug Deliv Technol. 2024;14(2):724-6. doi: 10.25258/ijddt.14.2.19.

Adhao VS, Chaudhari SP, Ambhore JP. Stability indicating RP-HPLC method development and validation for imeglimin hcl in pharmaceutical dosage form. Chem Sci Int J. 2024;33(4):1-10. doi: 10.9734/CSJI/2024/v33i4901.

Chikhale H, Ambekar Y, Avhad S, Borse L. Development and validation of RP-HPLC method for determination of antidiabetic drug (imeglimin HCL) in bulk and its dosage form. JCHR.2024;14(4):675-85.

Jain A, Soni LK, Sharma R. Development and validation of stability indicating RP-UHPLC method for the estimation of imeglimin hydrochloride used for the treatment of metabolic disorder diabetes mellitus. Int J Appl Pharm. 2023;15(6):211-7. doi: 10.22159/ijap.2023v15i6.49757.

Ramalingam S, Subramania MN, Basuvan B, Jaganathan R, Dhavamani AJ, Kandukuri NK. A sensitive direct chiral liquid chromatography tandem mass spectrometry method for the enantio selective analysis of imeglimin in formulation. J Appl Pharm Sci. 2023;13(7):214-19. doi: 10.7324/JAPS.2023.132349.

Ranjan PB, Prakash SR. Development and validation of imeglimin hydrochloride by UV/Visible spectrophotometric method. Int J Res Anal Rev. 2023;10(4):57.

Dange YD, Honmane SM, Bhinge SD, Salunkhe VR, Jadge DR. Development and validation of UV-spectrophotometric method for estimation of metformin in bulk and tablet dosage form. Indian J Pharm Educ Res. 2017;51(4s):s754-60. doi: 10.5530/ijper.51.4s.109.

Ficarra R, Calabro ML, Cutroneo P, Tommasini S, Melardi S, Semreen M. Validation of a LC method for the analysis of oxaliplatin in a pharmaceutical formulation using an experimental design. J Pharm Biomed Anal. 2002;29(6):1097-103. doi: 10.1016/S0731-7085(02)00151-6, PMID 12110395.

ICH. Validation of analytical procedures: text and methodology; 2005;Q2(R1). Available from: https://database.ich.org/sites/default/files/Q2%28R1%29%20Guideline.pdf. [Last accessed on 15 Feb 2025].

Hinge MA, Patel D. Optimization of HPLC method using central composite design for estimation of torsemide and eplerenone in tablet dosage form. Braz J Pharm Sci. 2022;58:e20219. doi: 10.1590/s2175-97902022e20219.

S Lakka N, Kuppan C. Principles of chromatography method development. In: Boldura OM, Balta C, Sayed Awwad N, editors. Biochemical analysis tools methods for bio-molecules studies. IntechOpen; 2020. doi: 10.5772/intechopen.89501.

Andrade C. The P value and statistical significance: misunderstandings explanations challenges and alternatives. Indian J Psychol Med. 2019;41(3):210-5. doi: 10.4103/IJPSYM.IJPSYM_193_19, PMID 31142921.

Kim TK. Understanding one way ANOVA using conceptual figures. Korean J Anesthesiol. 2017;70(1):22-6. doi: 10.4097/kjae.2017.70.1.22, PMID 28184262.

Hinge MA, Patel D. Optimization of HPLC method using central composite design for estimation of torsemide and eplerenone in tablet dosage form. Braz J Pharm Sci. 2022;58:e20219. doi: 10.1590/s2175-97902022e20219.

Beg S, Swain S, Rahman M, Hasnain MS, Imam SS. Application of design of experiments (DoE) in pharmaceutical product and process optimization. In: pharmaceutical quality by design. Amsterdam: Elsevier; 2019. p. 43-64. doi: 10.1016/B978-0-12-815799-2.00003-4.

Adhao VS, Chaudhari SP, Ambhore JP. Stability indicating RP-HPLC method development and validation for imeglimin HCL in pharmaceutical dosage form. Chem Sci Int J. 2024;33(4):1-10. doi: 10.9734/CSJI/2024/v33i4901.

Gogikar SK, Sen S, Pathinti S, Samanthula G, Dikundwar AG. Forced degradation study of an anti‐diabetic drug imeglimin: impurity profiling and structure elucidation using LC‐Q‐ToF‐MS/MS and NMR. Rapid Commun Mass Spectrom. 2025;39(5):e9960. doi: 10.1002/rcm.9960, PMID 39658818.

ICH. Impurities in new drug substances; 2006:Q3A(R2). Available from: https://database.ichorg/sites/default/files/Q3A%28R2%29%20Guideline.pdf. [Last accessed on 02 Mar 2025].

Ofrydopoulou A, Nannou C, Evgenidou E, Lambropoulou D. Sample preparation optimization by central composite design for multi class determination of 172 emerging contaminants in wastewaters and tap water using liquid chromatography high resolution mass spectrometry. J Chromatogr A. 2021 Aug 30;1652:462369. doi: 10.1016/j.chroma.2021.462369, PMID 34246959.

Mubeen G, Navali S, NL. RP-HPLC method for determination of imeglimin hydrochloride in bulk and tablet formulation. Asian J Pharm Res Dev. 2024;12(4):92-6. doi: 10.22270/ajprd.v12i4.1446.